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This study seeks to understand whether people substitute between recreational cannabis and conventional over-
the-counter (OTC) sleep medications. UPC-level grocery store scanner data in a multivariable panel regression 
design were used to compare the change in the monthly market share of sleep aids with varying dispensary-
based recreational cannabis access (existence, sales, and count) in Colorado counties between 12/2013 and 12/ 
2014. We measured annually-differenced market shares for sleep aids as a portion of the overall OTC medication 
market, thus accounting for store-level demand shifts in OTC medication markets and seasonality, and used the 
monthly changes in stores’ sleep aid market share to control for short-term trends. Relative to the overall OTC 
medication market, sleep aid market shares were growing prior to recreational cannabis availability. The trend 
reverses (a 236% decrease) with dispensary entry (−0.33 percentage points, 95% CI −0.43 to −0.24, 
p < 0.01) from a mean market share growth of 0.14 ± 0.97. The magnitude of the market share decline 
increases as more dispensaries enter a county and with higher county-level cannabis sales. The negative asso-
ciations are driven by diphenhydramine- and doxylamine-based sleep aids rather than herbal sleep aids and 
melatonin. These findings support survey evidence that many individuals use cannabis to treat insomnia, al-
though sleep disturbances are not a specific qualifying condition under any U.S. state-level medical cannabis 
law. Investigations designed to measure the relative effectiveness and side effect profiles of conventional OTC 
sleep aids and cannabis-based products are urgently needed to improve treatment of sleep disturbances while 
minimizing potentially serious negative side effects. 
1. Introduction 
About 50% of the adult population in the United States (US) ex-
periences sleeping problems, with the highest rates among women and 
older people,1–4 and other socio-demographic subgroups (e.g., college 
students).5 Sleep disturbances including insomnia, short or long sleep, 
and sleep apnea not only create economic burdens on society in terms 
of medical costs and lost productivity,6–8 but are well-established risk 
factors for mental and physical health conditions, including depres-
sion,9,10 cognitive impairment,11,12 chronic pain,13 obesity, vascular 
diseases,14 and overall mortality.15,16 Sleep disorders are typically 
treated with cognitive and behavioral therapies and/or prescription 
pharmaceuticals, namely anti-depressants, benzodiazepines, gamma-
aminobutyric acid (GABA) medications, and anti-psychotics, each with 
their own set of side effects, risk profiles, and dangerous drug interac-
tions.17–19 Over-the-counter (OTC) medications including anti-
histamines (e.g., diphenhydramine and doxylamine), melatonin 
(available in natural and synthetic forms), and natural products like 
valerian, are generally believed to be a safer alternative, but tend to be 
less efficacious, can carry negative side effects (e.g., headaches, con-
fusion, agitation) including vascular disturbances, and in the case of 
diphenhydramine, are generally not recommended for older 
people.2,20–25 For example, chronic use of sedating antihistamines such 
as diphenhydramine can increase mortality among the elderly and this 
medication together with all hypnotics are in Beer’s list of medications 
contraindicated for geriatric population.26 Current risks and limitations 
of treating sleep disturbances with conventional pharmaceutical med-
ications have created the opportunity for alternative therapies to 
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compete for consumer spending, including cannabis, which is becoming 
increasingly popular and accessible through state-legal medical and 
recreational dispensaries across the US. 
This study uses retail scanner data to measure the effect of recrea-
tional cannabis access on sales of OTC sleep aids in Colorado between 
12/2013 and 12/2014. Colorado is an ideal environment for assessing 
the impact of cannabis on OTC medications due to heterogeneity in the 
timing and extent of recreational cannabis access across counties and 
the pre-existing and relatively mature medical cannabis program. We 
focus on the impact of recreational dispensaries on OTC sleep aid 
medications because recreational dispensaries enabled the general 
public to legally use cannabis for improving sleep. Pre-existing medical 
programs throughout the US (including those in Colorado) do not in-
clude sleep disturbances as a specific authorized condition, although 
some regions (e.g., Washington, DC, but not Colorado) do allow pro-
viders to refer individuals with any severe, debilitating condition. 
However, severe, debilitating sleep disorders are unlikely to be treated 
with OTC sleep aids, making the population affected by recreational 
access likely much larger than that affected by medical dispensary ac-
cess alone. Using a quasi-experimental difference-in-differences re-
gression approach to compare market share growth in OTC sleep aids in 
counties pre- and post-recreational dispensary entry, we examine the 
research questions: 1) Is access to recreational cannabis via dispensaries 
associated with changes in purchases of OTC sleep aids? and 2) Does 
this association differ by category of OTC sleep aid, i.e., pharmaceutical 
(diphenhydramine and doxylamine) and supplements (melatonin and 
herbal products)? During the period of our data sample (2012 to 2014), 
the U.S. market for OTC sleep aids grew more than 37% from $570 M to 
$780M in inflation-adjusted dollars.27 However, based on previous 
research showing legal access to medical cannabis reduces the use of 
multiple scheduled prescription medications, including those used for 
treating pain and sleep disorders,28–30 we hypothesize that recreational 
cannabis access reduces the market for OTC sleep aids. 
2. Methods 
2.1. Data 
We extracted data on the OTC medication market from retail 
scanner data supplied by Nielsen through the Kilts Center for 
Marketing. The Nielsen data cover 50% of grocery store commodity 
volume, 32% of mass merchandiser sales (e.g., Target), and 1–2% of 
liquor and convenience stores. The retail scanner data include all pro-
duct sales as recorded by check-out scanners for the stores in the 
Nielsen sample, with the underlying unit of observation the individual 
product-level Universal Product Code (UPC) data (sales and units), in-
cluding encoded store identifiers. Nielsen does not report specific pro-
duct ingredients. The underlying data used in our main analysis in-
cludes all stores with non-zero monthly unit sales of any OTC sleep aids 
for all months between 11/2012 and 12/2014. This restriction ensures 
that we study stores that consistently stock and sell sleep aids. For our 
category analysis, we used online manufacturer descriptions to identify 
active ingredients and group our variables into two product categories: 
supplements (herbal products and melatonin) and pharmaceuticals 
(diphenhydramine and doxylamine.) Our category sample includes all 
stores with positive sales of both of the product categories, supplements 
and pharmaceuticals, for all months in our sample period. 
2.2. Measures 
For our main outcome variable, the annual growth in monthly OTC 
sleep aids market share, we begin by dividing unit sales of OTC sleep 
aids by unit sales of all OTC medications for each store for each month 
between 11/2012 and 12/2014. Using market shares rather than raw 
sales allows us to incorporate the size of a store’s overall market for 
OTC medications into our outcome variable, a common approach for 
estimating population-level effects using Nielsen data.31 (Required 
disclaimer: All results are “calculated (or derived) based on data from 
The Nielsen Company (US), LLC and marketing databases provided by 
the Kilts Center for Marketing Data Center at The University of Chicago 
Booth School of Business.”) This also avoids conflating shifts in demand 
for OTC sleep aids with shifts in demand for all OTC medications. For 
our category analysis, we calculate the market shares by active in-
gredient group relative to the overall market for OTC sleep aids, leaving 
us with two observations (one for pharmaceuticals; one for supple-
ments) for each store-month. 
We then adjust our market share measures to account for season-
ality by subtracting the market share in a given month-year from the 
market share in the same month the prior year, so that our outcome 
variable uses data from 11/2012-12/2014 to measure the market share 
growth in OTC sleep aids between 12/2013 to 12/2014. We also in-
clude the month-to-month lag of market share growth as an in-
dependent variable in order to account for store-level short-term trends 
stimulated by, for example, temporary changes in display location or 
neighborhood promotional circulars. For our main analysis of overall 
sleep aids, 587 stores with 13 month-level observations per store were 
analyzed, resulting in a total of 7631 store-months. Including only 
store-months with product sales of both sub-categories of sleep aids 
leaves 410 stores (due primarily to some stores not selling the supple-
ments category of products every month) and 10,660 store-product-
level observations. Revenues and prices are in nominal U.S. dollars. 
Our exposure variable is county-level recreational cannabis access 
by month. Recreational cannabis became legally available for purchase 
from dispensaries in Colorado on 1/1/2014. Unlike at medical cannabis 
dispensaries, which first opened in Colorado on 6/7/2010, recreational 
cannabis can be purchased without a doctor’s referral, essentially over-
the-counter. Monthly dispensary access varied during this time from 0, 
including some counties (and cities) that banned the sale of recreational 
cannabis, to a maximum of 101 in Denver County. We use three mea-
sures of recreational cannabis access: the existence of any recreational 
dispensaries, recreational cannabis sales, and the total number of re-
creational dispensaries in each county in each month as reported by the 
Colorado Department of Revenue.32 Dispensary zip codes were matched 
to counties using the US Department of Housing and Urban Develop-
ment’s zip code-county crosswalk for the first quarter of 2014. The 
Colorado Department of Revenue reports county-level recreational and 
medical cannabis sales based on tax returns filed by Colorado dis-
pensaries, which we categorized as $0 sales, sales of $1 to $500,000, 
and sales over $500,000. Confidentiality exceptions exist for counties 
with fewer than three recreational cannabis dispensaries or if one dis-
pensary accounts for more than 80% of reported sales for that county-
month. We code these counties in the $1 to $500,000 category. Monthly 
county-level recreational cannabis access was matched with store 
market share data on the basis of each store’s county, as reported in the 
Nielsen data. Descriptive statistics for all variables are shown in 
Table 1. Fig. 1 shows the expansion of recreational dispensary access 
across Colorado counties between 12/2012 and 12/2014. 
2.3. Statistical analysis 
We used ordinary least squares regressions to analyze the associa-
tion between recreational cannabis access and OTC sleep aids market 
share growth, regressing the OTC sleep aids market share growth on 
three county-level measures of recreational cannabis access: existence 
of any recreational cannabis dispensary; recreational cannabis sales 
($0, $1-500,000, or greater than $500,000); and the number of re-
creational cannabis dispensaries active that month. For our analysis by 
sleep aid category, we examine the interaction between an indicator 
variable for the supplement category with our measures of recreational 
cannabis access to estimate the differential association of access on 
supplements’ market share growth relative to its association with 
market share growth in the pharmaceutical product category. 
Table 1 
Descriptive Statistics for Regression Samples. 
Mean SD Minimum Maximum 
Panel A: Store-Level OTC Sleep Aids Market Information 
(587 stores, 7631 store-months) 
Any Dispensary 0.69 0.46 0.00 1.00 
Number of Dispensaries 14.41 30.79 0.00 119.00 
Revenue = $0 0.43 0.50 0.00 1.00 
Revenue $1-500K 0.19 0.39 0.00 1.00 
Revenue $500K+ 0.38 0.49 0.00 1.00 
Sleep Aids Sales (units) 94.38 73.52 1.00 613.00 
OTC Medication Sales (units) 2,841 2,150 181 19,227 
Sleep Aids Share of OTC 3.41 1.10 0.21 18.57 
Market x 100 
Sleep Aids Market Share 0.14 0.97 −10.27 12.66 
Growth x 100 
One Month Lagged Market 0.18 0.97 −7.36 12.66 
Share Growth x 100 
Medical Cannabis Patients 8,917 6,411 31 20,186 
Population 397,635 237,185 3,537 665,052 
Medical Cannabis Patients/ 2.12 0.66 0.68 4.85 
Population (%) 
Sleep Aids Price ($) 7.02 2.27 1.34 13.25 
Sleep Aids Price Growth ($) 0.06 0.85 −6.47 4.44 
Number of Sleep Aids UPCs 45.79 24.91 1.00 136.00 
Growth in Sleep Aids UPCs 2.77 9.42 −38.00 50.00 
(UPCs) 
Panel B: Market Information by Product Category 
(410 stores, 820 store-product categories, 5330 store-months per product 
category) 
Pharmaceutical Sleep Aids 
Sales (units) 108.40 64.77 5.00 551.00 
Market Share x 100 87.39 6.91 33.33 99.29 
Market Share Growth x 100 2.94 7.05 −39.70 41.96 
Supplement Sleep Aids 
Sales (units) 13.79 8.88 1.00 80.00 
Market Share 12.61 6.91 0.71 66.67 
Market Share Growth −2.94 7.05 −41.96 39.70 
Notes: Total Observations refers to store-months in Panels A and store-product-
category-months in Panel B. (In Panel B, each store-month has one observation 
for pharmaceutical sleep aids and one observation for supplements.) Revenue 
variables are {0,1} variables for whether a store is in a county that falls into 
that revenue category. Sleep Aids Market Share refers to sleep aids sales divided 
by total over-the-counter medication sales. Sleep Aids Market Share Growth 
subtracts the current month's sleep aids market share from the sleep aids market 
share in the same month one year prior to difference out store-specific sea-
sonality. (Growth in Price per Dose and Growth in Number of UPCs are con-
structed similarly by subtracting the value from that month in the prior year.) 
Market shares are multiplied by 100 to facilitate interpretation of percentage 
point changes in the regression results. The underlying data range from 11/ 
2012 through 12/2014. 
In all our regressions, we control at the store-level for factors likely 
to affect demand for OTC sleep aids, including growth in the number of 
varieties of sleep aids within a product line (e.g., new dosages or 
numbers of doses in a package), price growth (per product and per dose 
in our store- and store-product-level analyses, respectively), and the 
lagged monthly market share growth in order to control for monthly 
changes in unobserved factors that affect product sales besides price 
and product variety. At the county-level, we control for population and 
the size of the medical cannabis market using the number of medical 
cannabis patients as a percent of a county’s 2010 population. Product 
characteristics are based on the underlying Nielsen data, medical can-
nabis patient information is from the Colorado Department of Public 
Health’s Medical Cannabis Registry, and county-level population data 
are from U.S. Census Bureau. In each analysis, we also create separate 
intercepts (fixed effects) to control for time-invariant effects, i.e., fac-
tors that do not change over our sample period. We include store-level 
intercepts for our main analysis and store-category intercepts, i.e. store-
pharmaceutical or store-supplement, for our category analysis. We 
cluster our standard errors at the store level to control for hetero-
skedasticity and within-store error correlation. 
In Panel A of Fig. 2, we provide graphical support for the parallel 
trends assumption underlying our difference-in-differences estimation 
approach and the need to adjust for seasonality. Panel B of Fig. 2 de-
picts the stability over time of the denominator of our OTC sleep aids 
market share, OTC medications. 
Because Denver is such a clear outlier, due to its large number of 
recreational dispensaries and associated tourism, and hence the pro-
portion of individuals likely contributing to recreational cannabis 
purchases but not necessarily to local OTC medication purchases, we 
rerun our regressions omitting Denver as a robustness check. All ana-
lyses were conducted using Stata 14.2. 
3. Results 
Fig. 3 shows that before a dispensary opens, sleep aid market share 
growth was flat, but after entry the growth declined with each month. 
(Supplementary Appendix Fig. SA1 indicates that the sleep aids market 
share continued to decline with each additional dispensary.) Similarly, 
our regression results in Panel A of Table 2 show that sleep aid market 
share growth decreased by 236% or 0.33 percentage points (95% CI 
−0.43 to −0.24, p < 0.01) after dispensary entry (from a mean 
market share growth of 0.14 ± 0.97, measured from 1 to 100) and this 
negative association grew with the size of the recreational cannabis 
market. Comparing across product categories in Table 2, Panel B, we 
find that supplement market share growth increases with dispensary 
entry relative to that of pharmaceutical sleep aids, i.e., that decreases in 
the pharmaceutical market share growth drive the decrease in overall 
sleep aid market share growth following access to recreational can-
nabis. Our robustness check omitting Denver yields a similar pattern of 
results as reported in Supplemental Appendix Table SA1. 
4. Discussion 
Quality sleep is necessary for optimal mental and physical health, 
behavioral functioning, and wellbeing, and yet sleep disorders are 
pervasive in industrialized societies.2–5Conventional OTC pharmaceu-
tical sleeping aids have limited effectiveness,33,34 with 80% of con-
sumers reporting residual effects (e.g., drowsiness, concentrating and 
memory impairments) that can contribute to broader behavioral dis-
turbances (e.g., work absenteeism, non-work activities impairment).35 
Consumers of conventional sleeping medications report experimenting 
with an average of four types of sleep aids in the past year.26 With 
nearly 50% dissatisfaction rates,36 consumers may welcome alternative 
medication options. Our results show that the market share growth for 
sleep aids shrank with the entry of recreational cannabis dispensaries 
by more than 200% relative to the mean market share growth in our 
sample, and the strength of the association increased with each sub-
sequent dispensary. In particular, cannabis appears to compete favor-
ably with OTC sleep aids, especially those containing diphenhydramine 
and doxylamine, which constitute 87.4% of the market for OTC sleep 
aids. Cannabis access may also be associated with an increased pre-
ference for more natural sleep aids, such as melatonin and valerian. 
Our results are consistent with evidence that legal access to medical 
cannabis is associated with reductions in Scheduled II-V prescription 
medications (e.g., opioids and sedatives), many of which may be used 
in part as sleep aids.28–3037 Prescription sleep aids, namely anti-de-
pressants (e.g., trazodone, amitriptyline, and doxepin), benzodiaze-
pines (e.g., diazepam and lorazepam), GABA medications (zolpidem 
and eszopiclone), and anti-psychotics (aripiprazole, olanzapine, que-
tiapine and risperidone) come with practical and significant clinical 
drawbacks.17–19 For example, while tricyclic antidepressants and ben-
zodiazepines can improve certain sleep outcomes (e.g., latency to 
falling asleep), they can also cause somnolence and slow-wave inter-
ference (e.g., rapid eye movement [REM] sleep), and long-term use is 
Fig. 1. Dispensary Entry in Colorado 1/2014 to 12/2014. 
Notes: The maps show the increase in recreational cannabis access over time as dispensaries entered counties across Colorado. 
associated with a heightened risk for neurodegenerative disorders (e.g., 
Alzheimer’s disease), malignancy, and death by suicide and accidental 
poisoning.38–41 
For the first time, we show a statistically significant negative asso-
ciation between recreational access to cannabis and OTC sleep aid sales, 
suggesting that at least some recreational purchasers are using cannabis 
for therapeutic rather than recreational purposes. Additionally, despite 
a lack of direct clinical evidence on the effectiveness of self-managed 
cannabis as a sleep aid, our results indicate that enough individuals are 
switching from OTC sleep aids to recreational cannabis that we can 
identify a statistically significant reduction in the market share growth 
of OTC sleep aids in conjunction with access to recreational cannabis 
using a statistically conservative county-month-level treatment variable 
and a quasi-experimental research design. Recreational cannabis access 
likely increases cannabis demand in general for several economic and 
medical reasons, such as decreased transaction costs, reduced stigma, 
and cannabis tourism. Such access could increase specifically medicinal 
use of cannabis if, as our results suggest, cannabis improves sleep dis-
orders typically treated with OTC sleep aids. Sleep improvement, pos-
sibly alongside improvements in primary symptom management asso-
ciated with sleep disturbances such as pain and anxiety, could partially 
explain why cannabis is the most widely used substance in the U.S.42 
Substitution of cannabis for conventional sleep aids may also reflect a 
broader trend toward “natural” remedies as reflected in increased 
market share growth for supplement-based OTC sleep aids relative to 
diphenhydramine- and doxylamine-based sleep aids. 
The plant has been investigated as a potential treatment for a range 
of medical conditions from post-traumatic stress disorder to cancer, 
with the most consistent support for the treatment of chronic pain, 
epilepsy, and spasticity.42 The current results are consistent with 
survey-based studies showing increasing use of cannabis for improving 
sleep among patient populations with disparate diagnoses (e.g., post-
traumatic stress disorder (PTSD), Parkinson’s disease)43,44,45 and a 
mobile app-based study that measured the real-time effectiveness of 
using Cannabis flower for treating insomnia.46 Any potential ther-
apeutic benefits of cannabis use should, however, be weighed against 
the risks of using cannabis as a sleep aid. While clinical trials have 
shown that cannabis improves sleep in the short term,42 the risks of 
long-term use are unknown. Other sleep medications carry risks of dose 
escalation and dependence, and a similar risk of increased tolerance to 
the somnolent effects of cannabis and a subsequently increased risk of 
experiencing cannabis withdrawal syndrome, often characterized by 
disturbed sleep, may also occur. Regular cannabis use for sleep, and any 
rebound withdrawal symptoms when use is ceased, could promote 
continued cannabis use and increase the likelihood of developing can-
nabis dependence. Unfortunately, due to cannabis’ continued Schedule 
I status and associated barriers to conducting medical cannabis re-
search,47 no practical, naturalistic investigations have been completed 
on how patient-managed phytocannabinoid consumption affects long 
term sleep prognosis or even discrete mechanisms (e.g., ventrolateral 
preoptic nucleus activation, memory consolidation) and other basic 
characteristics (e.g., sleep stages, circadian rhythm) involved in normal 
and aberrant sleep patterns. 
Our study has limitations. We assume that OTC sleep aids are not 
commonly used for recreational purposes and that while cannabis 
substitutes for OTC sleep aids, the marginal benefit over locally ob-
tained OTC sleep aids is insufficient for individuals to travel a sig-
nificant distance to purchase cannabis products. If enough individuals 
are willing to travel to the next county to obtain cannabis rather than 
use an OTC sleep aid, our study may be underestimating the impact of 
recreational cannabis access on OTC sleep aid markets. Alternatively, 
we could be overestimating the effect of recreational cannabis access if 
consumers are shifting towards purchasing sleep aids, but not other 
OTC medications, from stores not in our data at the same time a dis-
pensary opens. However, the continued reductions in sleep aid market 
share growth with the entry of additional recreational cannabis stores 
Fig. 2. Testing Assumptions. 
Notes: We differentiate between counties in which a dispensary never opened (Non-Dispensary County) and counties in which at least one dispensary entered 
between 1/2014 and 12/2014 (Dispensary County). Panel A graphs the mean OTC sleep aids share (relative to all OTC medication unit sales) for all stores in our 
sample by month during 2013 by type of county. Panel B shows mean OTC Medication Unit Sales from 1/2013 through 12/2014 by type of county. 
supports that recreational cannabis access rather than an omitted 
variable is driving the reduction in sleep aids. It is interesting that total 
OTC medication sales remained basically unchanged regardless of 
presence or absence of recreational cannabis dispensaries, likely due to 
the small sleep aid market space (< 3.7% market share) relative to the 
Fig. 3. OTC Sleep Aids Market Share Growth 
Pre- and Post-First Dispensary Entry. 
Notes: Market Share Growth refers to the an-
nual growth in monthly market share of OTC 
sleep aids relative to the market for all OTC 
medications (in unit sales). The scatter plot 
shows the average market share growth for 
each month relative to the month of dispensary 
entry and include only data from counties in 
which at least one dispensary opened by 12/ 
2014. We also show trend lines fitted to the 
scatter plot by period, pre- and post-entry. 
overall OTC medication market. Future research should consider in-
vestigating the the overall and relative effects of recreational and 
medical cannabis access on OTC medication usage, given medical dis-
pensaries operate legally in more states than do recreational dis-
pensaries and existing research suggesting a decline in prescription 
Table 2 
Association between Sleep Aids Market Share Growth & Recreational Cannabis 
Access. 
(1) (2) (3) 
Panel A: Overall Sleep Aids Market Analysis (587 stores; 7631 store-months) 
Any Dispensary −0.334*** 
(−0.426 to 
−0.241) 
Revenue $1-500,000 −0.242*** 
(−0.315 to 
−0.170) 
Revenue $500,000+ −0.301*** 
(−0.368 to 
−0.235) 
Number of Dispensaries −0.005*** 
(−0.009 to 
−0.002) 
R-squared 0.218 0.219 0.212 
Panel B: Product Category Analysis (820 store-categories; 10,660 store-category-
months) 
Any Dispensary −0.543** 
(−1.032 to 
−0.054) 
Any Dispensary x 1.357** 
Supplement 
(0.107 - 2.607) 
Revenue $1-500,000 −0.656** 
(−1.244 to 
−0.069) 
Revenue $500,000+ −0.315 
(-0.970 - 0.340) 
Revenue $1-500,000 x 1.482** 
Supplement 
(0.014 - 2.951) 
Revenue $500,000+ x 1.520** 
Supplement 
(0.218 - 2.822) 
Number of Dispensaries −0.013** 
(−0.025 to 
−0.001) 
Number x Supplement 0.035 
(−0.008 -
0.078) 
R-squared 0.125 0.125 0.124 
Notes: Each column in each panel represents a separate regression. Coefficients 
from a least squares regression model are reported in line with the corre-
sponding variable with 95% confidence intervals below. Our outcome variable 
is the Sleep Aids Market Share Growth, or growth in the market share of sleep 
aids relative to the overall market for over-the-counter medications. Panel A 
reports results for the overall sleep aids market and Panel B identifies the dif-
ferential effect of recreational cannabis access on the supplement category of 
sleep aids relative to the pharmaceutical category of sleep aids. Observation 
counts are in store-months in Panel A and store-product category-months in 
Panel B. Revenue refers to recreational cannabis revenue only. The omitted 
Revenue category is Revenue = $0. All regressions include medical cannabis 
patients as a % of population, a previous month-level lag in the market share to 
control for store-level short-term trends in market shares, growth in prices, 
growth in the number of UPCs, and population. The top panel includes store-
level indicator variables (store-level fixed effects) and the bottom panel in-
cludes store-category indicator variables to control for time-invariant store and 
store-category characteristics. Growth variables compare the current value of 
each variable for a given month with the value for that month in the prior year 
in order to difference out store-specific seasonality. Standard errors are clus-
tered at the store level. p < 0.01 ***, p < 0.05 **, p < 0.1 *. 
drug use following access to medical dispensaries.28–30 
In conclusion, recreational cannabis dispensaries greatly increase 
the number of individuals able to legally treat sleep disorders using 
cannabis, particularly those with mild to moderate sleep disorders. The 
apparent use of cannabis as a sleep aid in this study underscores the 
importance of further medical research regarding its risk-benefit profile 
and the effectiveness of cannabis as a substitute for prescription sleep 
aids, which generally entail even greater risks to patients than OTC 
sleep aids. These issues are particularly important for older people, who 
tend to experience high rates of sleep disturbances, such as insomnia 
and sleep-disordered breathing,48 and heightened risk for cognitive 
impairment, dementia, depression, neurodegeneration, and Alzheimer’s 
diseases.10–1338–40 Despite the current lack of extensive medical evi-
dence, the market evidence suggests that many consumers may be 
opting to use cannabis for treating their sleep disturbances. 
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